Histamine suppresses in vivo and in vitro tumor growth in human triple-negative breast cáncer.

D MARTINEL LAMAS; E CARABAJAL; J CORTINA; RM BERGOC; ES RIVERA; VA MEDINA

Congreso; XLVIII Reunión Anual Sociedad Argentina de Investigación en Bioquímica y Biología Molecular.; 2012

The aim of this work was to evaluate the effect of histamine on survival, tumor growth rate, metastatic capacity and expression of antigens related with the proliferative and apoptotic potential in a triple negative breast cancer experimental model. Animals bearing xenografts of the human MDA-MB-231 cell line were treated with histamine (5 mg/Kg, sc). Results indicate that developed tumors were highly undifferentiated, exhibited high levels of H4R, histamine content and proliferation marker (PCNA) while displayed low level of apoptosis. Histamine treatment significantly increased median survival (80 vs. 60 days; Log-rank Mantel-Cox Test, P=0.0025; Gehan-Breslow-Wilcoxon Test, P=0.0158) while decreased tumor growth evidenced by an augment of the tumor doubling time (13.1±1.2 vs. 7.4±0.6, P